See more : Riley Exploration Permian, Inc. (REPX) Income Statement Analysis – Financial Results
Complete financial analysis of Harrow Health, Inc. (HROW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Harrow Health, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Akzo Nobel N.V. (AKZOF) Income Statement Analysis – Financial Results
- Mojo Data Solutions, Inc. (MJDS) Income Statement Analysis – Financial Results
- Shandong Liancheng Precision Manufacturing Co., Ltd (002921.SZ) Income Statement Analysis – Financial Results
- AccuStem Sciences Limited (ACMSY) Income Statement Analysis – Financial Results
- Brookfield Business Partners L.P. (BBU) Income Statement Analysis – Financial Results
Harrow Health, Inc. (HROW)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.harrowinc.com
About Harrow Health, Inc.
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 130.19M | 88.60M | 72.48M | 48.87M | 51.17M | 41.37M | 26.77M | 19.94M | 9.72M | 1.66M | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 39.64M | 25.38M | 18.21M | 14.46M | 16.75M | 16.52M | 13.51M | 9.83M | 5.21M | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 90.55M | 63.21M | 54.26M | 34.41M | 34.42M | 24.85M | 13.27M | 10.11M | 4.51M | 567.41K | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 69.55% | 71.35% | 74.87% | 70.41% | 67.26% | 60.07% | 49.56% | 50.70% | 46.42% | 34.18% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.88M | 3.05M | 11.08M | 2.41M | 2.08M | 825.00K | 413.00K | 739.00K | 332.00K | 236.66K | 1.62M | 1.30M | 111.55K | 194.59K | 2.97M | 1.99M | 1.83M | 150.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.96M | 17.57M | 12.50M | 8.09M | 5.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 430.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.06M | 7.38M | 6.50M | 2.39M | 85.89K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -423.79K |
| SG&A | 83.09M | 58.24M | 41.32M | 31.25M | 33.10M | 29.24M | 25.02M | 24.95M | 19.00M | 10.48M | 6.08M | 2.98M | 827.67K | 2.31M | 1.60M | 1.76M | 2.86M | 6.21K |
| Other Expenses | 0.00 | -15.93M | -19.49M | -3.80M | 630.00K | 103.00K | 0.00 | 1.54M | 31.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -110.00K |
| Operating Expenses | 90.12M | 61.29M | 52.40M | 33.66M | 35.18M | 30.07M | 25.43M | 25.69M | 19.33M | 10.71M | 7.70M | 4.28M | 939.23K | 2.50M | 4.56M | 3.75M | 2.86M | 46.21K |
| Cost & Expenses | 129.76M | 86.68M | 70.61M | 48.12M | 51.93M | 46.59M | 38.94M | 35.52M | 24.54M | 11.81M | 7.70M | 4.28M | 939.23K | 2.50M | 4.56M | 3.75M | 2.86M | 46.21K |
| Interest Income | 0.00 | 7.24M | 5.44M | 2.24M | 0.00 | 0.00 | 0.00 | 10.00K | 13.00K | 32.45K | 43.76K | 15.41K | 0.00 | 512.00 | 10.44K | 67.01K | 48.44K | 0.00 |
| Interest Expense | 21.32M | 7.24M | 5.44M | 2.24M | 2.50M | 2.73M | 3.03M | 6.00M | 1.12M | 3.80K | 0.00 | 24.66K | 75.00K | 55.48K | 0.00 | 0.00 | 1.56M | -10.00K |
| Depreciation & Amortization | 12.34M | 3.67M | 2.40M | 2.74M | 2.66M | 1.84M | 1.77M | 1.41M | 610.00K | 85.35K | 5.66K | 2.94K | 338.00 | 1.06K | 1.06K | 704.00 | 201.25K | 0.00 |
| EBITDA | 9.72M | -3.20M | -10.14M | 3.49M | 1.44M | -2.73M | -10.40M | -14.06M | -14.21M | -10.06M | -7.64M | -5.36M | -878.60K | -2.47M | -4.55M | -4.12M | -2.75M | -46.21K |
| EBITDA Ratio | 7.47% | 2.17% | 2.91% | 2.27% | 4.22% | -7.21% | -55.59% | -59.13% | -146.27% | -604.06% | -76,374.65% | -4,160.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 431.00K | -1.75M | -284.00K | -1.63M | -503.00K | -5.22M | -12.16M | -15.88M | -14.82M | -10.15M | -7.69M | -4.18M | -939.23K | -2.50M | -4.56M | -3.75M | -2.86M | -46.21K |
| Operating Income Ratio | 0.33% | -1.97% | -0.39% | -3.34% | -0.98% | -12.61% | -45.43% | -79.64% | -152.55% | -611.16% | -76,868.79% | -4,178.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -24.37M | -15.93M | -19.49M | -3.80M | 386.00K | 19.84M | -757.00K | -3.32M | -1.08M | 28.65K | 43.76K | -1.20M | -14.71K | -28.67K | 10.44K | 375.00K | -1.43M | -533.79K |
| Income Before Tax | -23.94M | -14.01M | -17.87M | -3.42M | -125.00K | 14.63M | -12.92M | -19.20M | -15.90M | -10.12M | -7.64M | -5.38M | -953.94K | -2.53M | 0.00 | -3.37M | -2.77M | -580.00K |
| Income Before Tax Ratio | -18.39% | -15.81% | -24.66% | -6.99% | -0.24% | 35.35% | -48.26% | -96.27% | -163.64% | -609.43% | -76,431.24% | -5,383.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 470.00K | 75.00K | 133.00K | 4.00K | 2.47M | -19.45M | -935.00K | -111.00K | 1.08M | -28.65K | -43.76K | 1.20M | -60.29K | -26.30K | -10.44K | -817.01K | -228.27K | 10.00K |
| Net Income | -24.41M | -14.09M | -18.01M | -3.42M | -2.59M | 14.63M | -11.99M | -19.09M | -15.90M | -10.12M | -7.64M | -5.38M | -953.94K | -2.53M | -4.55M | -3.30M | -4.28M | -46.21K |
| Net Income Ratio | -18.75% | -15.90% | -24.85% | -7.00% | -5.07% | 35.35% | -44.76% | -95.71% | -163.64% | -609.43% | -76,431.24% | -5,383.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.75 | -0.51 | -0.67 | -0.13 | -0.10 | 0.61 | -0.60 | -1.50 | -1.66 | -1.11 | -0.88 | -1.20 | -2.40 | -6.41 | -11.67 | -8.92 | -19.37 | -0.25 |
| EPS Diluted | -0.75 | -0.51 | -0.67 | -0.13 | -0.10 | 0.61 | -0.60 | -1.50 | -1.66 | -1.11 | -0.88 | -1.20 | -2.40 | -6.41 | -11.67 | -8.92 | -19.37 | -0.25 |
| Weighted Avg Shares Out | 32.62M | 27.46M | 26.76M | 25.90M | 25.32M | 23.81M | 19.98M | 12.74M | 9.58M | 9.13M | 8.66M | 4.49M | 397.80K | 394.63K | 390.32K | 370.55K | 221.17K | 185.01K |
| Weighted Avg Shares Out (Dil) | 32.62M | 27.46M | 26.76M | 25.90M | 26.47M | 23.81M | 20.03M | 12.74M | 9.58M | 9.13M | 8.66M | 4.49M | 397.80K | 394.63K | 390.32K | 370.55K | 221.17K | 185.01K |
Are AI Stocks A Better Investment Then Value Stocks?
Harrow: Bulls On Parade
Harrow (HROW) Reports Q2 Loss, Tops Revenue Estimates
Don't Buy AI Stocks, Buy The Best Dividend Total Return Stocks
Harrow (HROW) Is a Great Choice for 'Trend' Investors, Here's Why
Top 3 Health Care Stocks That May Crash This Quarter
Harrow Successfully Manufactures Triesence; Management Credibility Soars
Harrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?
Harrow Provides TRIESENCE® Relaunch Update
The Top 7 Growth Stocks to Buy and Hold Until 2030
Source: https://incomestatements.info
Category: Stock Reports